



## Årsrapport 2017

**Key numbers 2017:** 39 international publications, 11 national publications, 30 posters, 44 oral presentations/external lectures, 13 media coverages, 6 visits from international guest lecturers

**Key numbers 2016:** 25 international publications, 11 national publications, 26 posters, 25 oral presentations/externallectures, 31 media coverages

---

### International publications

1. **Lupattelli A, Wood M, Ystrom E, Skurtveit S, Handal M, Nordeng H.** Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Age Children. JAACAP. Online first: 28 Dec 2017. DOI: <http://dx.doi.org/10.1016/j.jaac.2017.12.010>.
2. Svendsen K, **Wood M**, Olsson E, **Nordeng H.** Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®. Eur J Clin Pharmacol. 2017 Dec 30. doi: 10.1007/s00228-017-2407-z.
3. **Salvatore S**, Domanska D, **Wood M, Nordeng H, Sandve GK.** Complex patterns of concomitant medication use: A study among Norwegian women using paracetamol during pregnancy. PLoS One. 2017 Dec 28;12(12):e0190101. doi:10.1371/journal.pone.0190101.
4. **Ystrom E**, Gustavson K, Brandlistuen RE, Knudsen GP, Magnus P, Susser E, Davey Smith G, Stoltenberg C, Surén P, Håberg SE, Hornig M, Lipkin WI, **Nordeng H**, Reichborn-Kjennerud T. Prenatal Exposure to Acetaminophen and Risk of ADHD. Pediatrics 2017 Nov; 140 (5). pii: e20163840.
5. **Wood ME**, Lapane KL, van Gelder MMHJ, Rai D, **Nordeng HME.** Making fair comparisons in pregnancy medication safety studies: An overview of advanced methods for confounding control. Pharmacoepidemiol Drug Saf 2017 Oct 17. doi:10.1002/pds.4336.
6. **Wood ME**, Chrysanthopoulou S, **Nordeng HME**, Lapane KL. The Impact of Nondifferential Exposure Misclassification on the Performance of Propensity Scores for Continuous and Binary Outcomes: A Simulation Study. Med Care. 2017 Sep 15. doi: 10.1097/MLR.0000000000000800.
7. Holdø I, Bramness JG, Handal M, Torgersen L, Reichborn-Kjennerud T, **Ystrøm E, Nordeng H, Skurtveit S.** Hypnotics use in children 0-18 months: moderate agreement between mother-reported survey data and prescription registry data. J Pharm Policy Pract 2017 Sep 8; 10: 28.
8. Bjelland EK, Owe KM, **Nordeng HME**, Engdahl BL, Kristiansson P, Vangen S, Eberhard-Gran M. Does progestin-only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective population study. PLoS One 2017 Sep 11; 12 (9):e0184071.
9. **Lupattelli A, Wood M**, Lapane K, Spigset O, **Nordeng H.** Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: A study from The Norwegian Mother and Child Cohort Study. Pharmacoepidemiol Drug Saf. 2017 Oct; 26(10):1266-1276.
10. **Gervin K, Nordeng H, Ystrom E**, Reichborn-Kjennerud T, **Lyle R.** Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children diagnosed with ADHD. Clin Epigenetics. 2017 Aug 2;9:77.
11. **Truong BT, Lupattelli A**, Kristensen P, **Nordeng H.** Sick leave and medication use in pregnancy: a European web-based study. BMJ Open. 2017 Aug 3;7(8):e014934.
12. Brandlistuen RE, **Ystrom E**, Hernandez-Diaz S, Skurtveit S, Selmer R, Handal M, **Nordeng H.** Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. PLoS One. 2017 Jul 26;12(7):e0181042.
13. **Harris GE, Wood M**, Eberhard-Gran M, Lundqvist C, **Nordeng H.** Patterns and predictors of analgesic use in pregnancy: a longitudinal drug utilization study with special focus on women with migraine. BMC Pregnancy Childbirth. 2017 Jul 14;17(1):224.
14. Kaplan YC, Karadaş B, Küçüksoğak G, Ediz B, Demir Ö, Sozmen K, **Nordeng H.** Counselling pregnant women at the crossroads of Europe and Asia: effect of Teratology Information Service in Turkey. Int J Clin Pharm. 2017 Aug;39(4):783-790.

15. **Trønnes JN, Lupattelli A, Nordeng H.** Safety profile of medication used during pregnancy: results of a multinational European study. *Pharmacoepidemiol Drug Saf.* 2017 Jul;26(7):802-811.
16. Heitmann K, **Nordeng H**, Havnen GC, Solheimsnes A, Holst L. The burden of nausea and vomiting during pregnancy: severe impacts on quality of life, daily life functioning and willingness to become pregnant again - results from a cross-sectional study. *BMC Pregnancy Childbirth.* 2017 Feb 28;17(1):75.
17. Mårdby AC, **Lupattelli A**, Hensing G, **Nordeng H.** Consumption of alcohol during pregnancy-A multinational European study. *Women Birth.* 2017 Aug;30(4):e207-e213.
18. Kjeldgaard HK, Eberhard-Gran M, Benth JŠ, **Nordeng H**, Vikanes ÅV. History of depression and risk of hyperemesis gravidarum: a population-based cohort study. *Arch Womens Ment Health.* 2017 Jun;20(3):397-404.
19. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Sætre E, Molden E, **Granås AG**, Johannessen SI, Landmark CJ. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. *Epilepsy Res.* 2017 online Nov 11;139:35-42.
20. Eek AK, Øie E, **Granås AG.** Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments. *Eur J Clin Pharmacol.* 2017 Nov 17. doi: 10.1007/s00228-017-2374-4.
21. Bell HT, Steinsbekk A, **Granås AG.** Elderly users of fall-risk-increasing drug perceptions of fall risk and the relation to their drug use - a qualitative study. *Scand J Prim Health Care.* 2017 Sep;35(3):247-255.
22. Costa FA, Scullin C, Al-Taani G, Hawwa AF, Anderson C, Bezverhni Z, Binakaj Z, Cordina M, Foulon V, Garcia de Bikuña B, de Gier H, **Granås AG**, Grinstova O, Griese-Mammen N, Grincevicius J, Grinceviciene S, Kaae S, Kubiliene L, Mariño EL, Martins S, Modamio P, Nadin G, Nørgaard LS, Obarcanin E, Tadic I, Tasic L, McElnay JC, Hersberger KE, Westerlund T. Provision of pharmaceutical care by community pharmacists across Europe: Is it developing and spreading? *J Eval Clin Pract.* 2017 Aug 1. doi: 10.1111/jep.12783.
23. **Granås AG**, Stendal Bakken M, Ruths S, Taxis K. Deprescribing for frail older people - Learning from the case of Mrs. Hansen. *Res Social Adm Pharm.* 2017 Jul 13. pii: S1551-7411(17)30588-0.
24. Bell HT, **Granås AG**, Enmarker I, Omli R, Steinsbekk A. Nurses' and pharmacists' learning experiences from participating in interprofessional medication reviews for elderly in primary health care - a qualitative study. *BMC Fam Pract.* 2017 Feb 28;18(1):30.
25. Mevaag M, Henning O, Baftiu A, **Granås AG**, Johannessen SI, Nakken KO, Johannessen Landmark C. Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs. *Acta Neurol Scand.* 2017 Jan;135(1):80-87. doi: 10.1111/ane.12578.
26. **Svensberg K**, Brandlistuen RE, **Björnsdottir I**, Sporrang SK. Factors associated with pharmacy students' attitudes towards learning communication skills - A study among Nordic pharmacy students. *Res Social Adm Pharm.* 2017 Mar 28. pii:S1551-7411(16)30598-8.
27. **Svensberg, Karin Anna Evelina**; Björnsdottir, Ingunn; Wallman, Andy; Sporrang, Sofia K. Nordic Pharmacy Schools' Experience in Communication Skills Training. *American Journal of Pharmaceutical Education* 2017 ;Volum 81.(9) s. 24-35.
28. Andrade S, Bérard A, **Nordeng H**, **Wood M**, van Gelder M, Toh S. Administrative Claims Data Versus Augmented Pregnancy Data for the Study of Pharmaceutical Treatments in Pregnancy. *CurrEpidemiol Rep* (2017) 4: 106. <https://doi.org/10.1007/s40471-017-0104-1>.
29. **Nordeng H, Lupattelli A, Wood M.** Prenatal exposure to antidepressants and increased risk of psychiatric disorders. *BMJ* (2017) 358:doi: <https://doi.org/10.1136/bmj.j3950> .
30. Abel, Marianne Hope; **Ystrøm, Eivind**; Caspersen, Ida Henriette; Meltzer, Helle Margrete; Aase, Heidi; Torheim, Liv Elin; Askeland, Ragna Bugge; Reichborn-Kjennerud, Ted; Brantsæter, Anne Lise. Maternal iodine intake and offspring attention-deficit/hyperactivity disorder: Results from a large prospective cohort study. *Nutrients* 2017 ;Volum 9.(11)
31. Eilertsen, Espen Moen; Gjerde, Line C.; Reichborn-Kjennerud, Ted; Ørstavik, Ragnhild; Knudsen, Gun Peggy; Stoltenberg, Camilla; Czajkowski, Nikolai Olavi; Røysamb, Espen; Kendler, Kenneth S; **Ystrøm, Eivind.** Maternal

alcohol use during pregnancy and offspring attention-deficit hyperactivity disorder (ADHD): a prospective sibling control study. *International Journal of Epidemiology* 2017 s.

32. Gjerde, Line C.; Eilertsen, Espen Moen; Reichborn-Kjennerud, Ted; McAdams, Tom A.; Zachrisson, Henrik Daae; Zambrana, Imac Maria; Røysamb, Espen; Kendler, Kenneth S.; **Ystrøm, Eivind**. Maternal perinatal and concurrent depressive symptoms and child behavior problems: a sibling comparison study. *Journal of Child Psychology and Psychiatry and Allied Disciplines* 2017 ;Volum 58.(7) s. 779-786

33. Long, Elizabeth C.; Aggen, Steven H.; Neale, Michael Churton; Knudsen, Gun Peggy; Krueger, Robert Frederick; South, Susan Carol; Czajkowski, Nikolai Olavi; Nesvåg, Ragnar; **Ystrøm, Eivind**; Torvik, Fartein Ask; Kendler, Kenneth Seedman; Gillespie, Nathan A.; Reichborn-Kjennerud, Ted. The association between personality disorders with alcohol use and misuse: A population-based twin study. *Drug And Alcohol Dependence* 2017 ;Volum 174. s. 171-180

34. Reichborn-Kjennerud, Ted; Krueger, R F; **Ystrøm, Eivind**; Torvik, Fartein Ask; Rosenström, Tom Henrik; Aggen, S H; South, S C; Neale, M C; Knudsen, Gun Peggy; Kendler, K S; Czajkowski, Nikolai Olavi. Do DSM-5 Section II personality disorders and Section III personality trait domains reflect the same genetic and environmental risk factors?. *Psychological Medicine* 2017 ;Volum 47.(12) s. 2205-2215

35. Rosenström, Tom; Torvik, Fartein Ask; **Ystrøm, Eivind**; Czajkowski, Nikolai Olavi; Gillespie, Nathan A.; Aggen, Steven H.; Krueger, Robert F; Kendler, Kenneth S.; Reichborn-Kjennerud, Ted. Prediction of alcohol use disorder using personality disorder traits: a twin study. *Addiction* 2017 s. - FHI UiO

36. Rosenström, Tom; **Ystrøm, Eivind**; Torvik, Fartein Ask; Czajkowski, Nikolai Olavi; Gillespie, Nathan A.; Aggen, Steven H.; Krueger, Robert F.; Kendler, Kenneth S.; Reichborn-Kjennerud, Ted. Genetic and Environmental Structure of DSM-IV Criteria for Antisocial Personality Disorder: A Twin Study. *Behavior Genetics* 2017 ;Volum 47.(3) s. 265-277.

37. Torvik, Fartein Ask; **Ystrøm, Eivind**; Gustavson, Kristin; Rosenström, Tom Henrik; Bramness, Jørgen Gustav; Gillespie, N; Aggen, S H; Kendler, K S; Reichborn-Kjennerud, Ted. Diagnostic and genetic overlap of three common mental disorders in structured interviews and health registries. *Acta Psychiatrica Scandinavica* 2017 ;Volum 137.(1) s. 54-64.

38. **Ystrøm, Eivind**; Hysing, Mari; Torgersen, Leila; Ystrøm, Hilde Thorsen; Reichborn-Kjennerud, Ted; Sivertsen, Børge. Maternal Symptoms of Anxiety and Depression and Child Nocturnal Awakenings at 6 and 18 Months. *Journal of Pediatric Psychology* 2017 ;Volum 42.(10) s. 1156-1164.

39. Ystrøm, Hilde Thorsen; Nilsen, Wendy; Hysing, Mari; Sivertsen, Børge; **Ystrøm, Eivind**. Sleep Problems in Preschoolers and Maternal Depressive Symptoms: An Evaluation of Mother- and Child-Driven Effects. *Developmental Psychology* 2017 s.

#### **International Presentations:**

1. **Mollie Wood**. The impact of differential exposure misclassification on performance of propensity score methods for binary outcome models. Society for Epidemiologic Research, Seattle, USA, 21 -23 June 2017.
2. **Angela Lupattelli**. Effect of time-dependent SSRI exposure in pregnancy on child's neurobehavioral development by age 5. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
3. **Angela Lupattelli**. Maternal Use of Benzodiazepines and Z-Hypnotics during Pregnancy and Developmental Outcomes in Offspring at 5 Years of Age: Effect of Timing and Duration of Exposure. Visiting Scholar presentation, Center for Better Beginnings, Department of Pediatrics, School of Medicine, UCSD, 5th Dec 2017, San Diego, USA.
4. **Angela Lupattelli**. Addressing Safety of Medication use During Pregnancy: Results of the Norwegian Mother and Child Cohort Study and Opportunities for Future Research. Visiting Scholar presentation, Center for Better Beginnings, Department of Pediatrics, School of Medicine, UCSD, 13th Oct 2017, San Diego, USA.
5. **Hedvig Nordeng**. Medication Use and Safety During Pregnancy. Norwegian-Russian research seminar, Individualised drug treatment and patient safety May, 23-25 2017, St. Petersburg, Russia.

6. **Anne Gerd Granås.** Polypharmacy in elderly patients – tools for medication reviews. Norwegian-Russian research seminar. Individualised drug treatment and patient safety May, 23-25 2017, St. Petersburg, Russia.
7. **Anne Gerd Granås.** E-learning and “flipped classroom”. Individualised drug treatment and patient safety May, 23-25 2017, St. Petersburg, Russia.
8. Hien Thi Ngo, **Ingunn Björnsdóttir.** Media coverage of diagnosis and treatment of adhd in Norway. Nordic Social Pharmacy and Health Services Research Conference, 7th to 9th June 2017, Kuopio, Finland. Abstract published in issue Research in Social and Administrative Pharmacy, Vol. 13, Issue 3, e4.
9. **Ragnhild E Brandlistuen.** Association of prenatal exposure to benzodiazepines and child internalizing problems: a sibling-controlled cohort study. 28th ENTIS conference, Budapest, 2nd - 5th September 2017.
10. **Kristina Gervin.** Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children with ADHD. 28<sup>th</sup> ENTIS conference, Budapest, 2<sup>nd</sup> - 5<sup>th</sup> September 2017.
11. **Eivind Ystrom.** Paracetamol exposure in pregnancy and offspring ADHD: familial risk and confounding by indication. 28th ENTIS conference, Budapest, 2nd - 5th September 2017
12. **Anna Frank.** Risk factors for discontinuation of hypothyroid medication use in early pregnancy— A study from the Norwegian Mother and Child Cohort Study and the Medical Birth Registry of Norway. 28th ENTIS conference, Budapest, 2nd - 5th September 2017
13. **Robert Lyle.** Building Bridges Epigenetics Symposium. Prenatal exposure to paracetamol and association with ADHD. University of Helsinki/FIMM, Helsinki, Finland. 10th October 2017
14. **Robert Lyle.** Prenatal exposure to paracetamol and association with ADHD. Turku Centre for Biotechnology, Turku, Finland. 12<sup>th</sup> October 2017.
15. **Ingunn Björnsdóttir.** Samskipti lyfjafraeðinga við sjúklinga. Hvernig er samskiptaþjálfun í lyfjafraeðinami á Norðurlöndunum, og hvað segja lögin? (Farmasøytters kommunikasjon med pasienter. Hvordan er kommunikasjonstreningen i farmasistudieprogrammer i de nordiske landene, og hva sier lovgivningen? Dagur lyfjafraeðinnar (farmasiens dag), Reykjavik, Island, 4. November.
16. **Hedvig Nordeng.** Fetal effects of maternal medication use - where are we today? PhD dissertation seminar, Lund, September
17. **Hedvig Nordeng.** Drug Utilisation Studies in Pregnancy, EuroDURG, Glasgow, November
18. **Hedvig Nordeng,** Studying neurotoxicity of medications – the PharmaTox strategic Research Initiative, PhD dissertation seminar, Aarhus, 8<sup>th</sup> December

#### International posters:

1. **Anna Simone Frank,** et al. Patterns and predictors of hypothyroid medication use in relation to pregnancy: a drug utilization study. 33nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
2. **Angela Lupattelli,** et al. Use and avoidance of medications in pregnancy: an Italian perspective. 33nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
3. **Mollie Wood,** et al. Mediation analysis in sibling studies. 33<sup>rd</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
4. **Mollie Wood,** et al. The impact of differential exposure misclassification on performance of propensity score methods for binary outcome models. 33<sup>rd</sup> International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
5. **Jacqueline Cohen,** et al. Paternal antidepressant use as a negative control for maternal use. 33nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.
6. **Kristina Svensen,** et al. Simulating how lawyer reporting can affect signal detection in Vigibase, a spontaneous reporting database. 33nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal.

7. **Eivind Ystrom**, et al. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August, Montreal. Acetaminophen exposure in pregnancy and offspring ADHD: familial risk and confounding by indication.
8. **Jacqueline Cohen**, et al. Paternal antidepressant use as a negative control for maternal use. Society for Epidemiologic Research, Seattle, USA, 19 -21 June 2017.
9. **Jacqueline Cohen**, et al. Paternal antidepressant use as a negative control for maternal use. Society for Pediatric and Perinatal Epidemiologic Research, Seattle, USA, 21 -23 June 2017.
10. **Mollie Wood**, et al. The impact of differential exposure misclassification on performance of propensity score methods for binary outcome models. Society for Pediatric and Perinatal Epidemiologic Research, Seattle, USA, 21 - 23 June 2017
11. **Lene Maria Sundbakk**, et al. Prenatal exposure to benzodiazepines or z-hypnotics and behavioral problems at 5 years of age: A study from the Norwegian Mother and Child cohort study. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. 25-28 August 2017, Montreal.
12. Vukica Bogosavljevic, DejanStevanović, **Ingunn Björnsdóttir**. Pharmacological treatment approaches to adhd in Norway and Serbia. 3 minute thesis, Nordic Social Pharmacy and Health Services Research Conference, 7th to 9th June 2017, Kuopio, Finland. Abstract published in issue Research in Social and Administrative Pharmacy, Vol. 13, Issue 3, e4.
13. **Ingunn Björnsdóttir**. Illustrating the importance of quality: amphetamine and the Icelandic prescription registry. 77th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2017, Seoul, 10th – 14th September 2017.\*
14. Gro C. Havnen, Elisabet Nordmo, Solveig T. Holmsen, **Hedvig Nordeng**, Olav Spigset. Treatment of Multiple Sclerosis during Pregnancy and Lactation – updated National Treatment Guidelines in Norway, 28th ENTIS conference, Budapest, 2nd - 5th September 2017
15. Spildrejorde, Mari, Falck, Martin, Leithaug Magnus, **Gervin Kristina**, Fjerdingsstad Hege B., **Nordeng Hedvig**, Paulsen Ragnhild E, Eskeland, Ragnhild, **Lyle Robert**. Human Embryonic Stem Cells as a Model for Paracetamol Induced Epigenetic Deregulation and Neurotoxicity, 28th ENTIS conference, Budapest, 2nd - 5th September 2017
16. **Truong Bich**, **Ariansen Hilde**, **Nordeng Hedvig**. SafeStart – an intervention study to promote healthier pregnancies, 28th ENTIS conference, Budapest, 2nd - 5th September 2017

#### **International Workshops:**

Lotte Stig Nørgaard, Andy Wallman, **Ingunn Björnsdóttir**, Kjell H. Halvorsen, Lone Holst, Tove Hedenrud, Ulla Hedegaard. Pharmacy internship in the Nordic countries – Status and future. Nordic Social Pharmacy and Health Services Research Conference, 7th to 9th June 2017, Kuopio, Finland. Abstract published in issue Research in Social and Administrative Pharmacy, Vol. 13, Issue 3, e4.

#### **International guest lecturers:**

**Shane Desselle**, professor at Touro University and president of Applied Pharmacy Solutions, Seminar on U.S. Drug Use, Economics and Pricing, June 6<sup>th</sup>

**Tobias Kurth**, Professor of Public Health and Epidemiology and Director of the Institut of Public Health, Charité – Universitätsmedizin Berlin, Germany. What if the Results between Propensity Score and Standard Methods differ? May 3<sup>rd</sup>, 2017.

**Professor Michael Scott**, Northern Ireland, Medicine Optimisation - What is it? And why we need it. March 20th 2017

**Helga Garðarsdóttir**, assistant professor of Drug Regulatory Sciences at Utrecht University, The Netherlands  
“Possible Savings on the Pharmaceuticals Budget by focusing on Reduction of Waste - The Dutch approach, March 16<sup>th</sup> 2017.

**Rúna Hauksdóttir Hvannberg**, director of the Icelandic Medicines Agency and previously chairman of the Icelandic Pharmaceuticals Pricing and Reimbursement Committee and lecturer in pharmacoconomics at the University of

Iceland. Pharmacoeconomics as a tool for rational reimbursement decision making. A case from Iceland, Feb 1<sup>st</sup> 2017.

**Ulrika Nörby**, researcher at the Stockholm County Council, department of E-health and Strategic IT, responsible for the Swedish knowledge database "Drugs and Birth Defects" ([www.janusinfo.se/fosterpaverkan](http://www.janusinfo.se/fosterpaverkan)). Fetal effects of maternal drug treatment - risk assessment and communication. Oct 23<sup>rd</sup> 2017.

## NATIONAL RESULTS

### National articles, editorials, chapters and clinical guidelines:

1. Kristina Gervin, Hedvig Nordeng, Ragnhild Eskeland, Ragnhild E. Paulsen og Robert Lyle Farmakoepigenetikk – samspillet mellom epigenetikk og legemidler. Norsk Farmaceutisk Tidsskrift 2017
2. Holmsen ST, Havnen GC, Nordmo E, Nordeng H, Spigset O. Re: Familieplanlegging, graviditet og amming ved multipel sklerose. Tidsskr Nor Laegeforen. 2017 Jan 10;137(1):9.
3. **Svensberg, Karin**; Bell, Hege Therese. Forskerspirer i samfunnsfarmasi og klinisk farmasi. Norsk Farmaceutisk Tidsskrift 2017 (4) s. 35-35.
4. Halvorsen L, Hoel KA, **Granås AG**. Tverrprofesjonelle legemiddelgjennomganger i hjemmebaserte tjenester; en utfordring? Geriatrisk sykepleie 2017 (3) s. 8-15.
5. Elizabeth Aa, Sylvia Granlund, Kristin Midtdal, Hege Salvesen Blix, Lars Gunnar Johnsen, **Anne Gerd Granås**. Hvem følger opp sykehusepikriser – fastlegen eller pasienten? Norsk Farmaceutisk Tidsskrift 2017 -10.
6. **Anne Gerd Granås**, Sabine Ruths, Anette Hylene Ranhoff, Aina Langørgen, Olav Spigset, Marit Stordal Bakken. Norsk oversettelse av forskrivningsverktøyet STOPPFrail. Avmedisinering av skrøpelige eldre med begrenset forventet levetid. Norsk Farmaceutisk Tidsskrift 2017 -9.
7. **Anne Gerd Granås**, Kronikk: Hvorfor tar ikke flere influensavaksinen i Norge? <https://www.dagensmedisin.no/artikler/2017/10/28/hvorfor-tar-ikke-flere-influensavaksinen-i-norge/>
8. **Anne Gerd Granås**, Kronikk: Gentester kan skape stress og uro. Men de kan også avdekke sykdomsrisiko. Hva gjør vi med dem? <https://www.aftenposten.no/viten/i/yeX3g/Gentester-kan-skape-stress-og-uro-Men-de-kan-ogsaa-avdekke-sykdomsrisiko-Hva-gjor-vi-med-dem>
9. **Anne Gerd Granås**, Kronikk: Suksess med vaksiner i USAs apotek – hva med Norge? Norsk Farmaceutisk Tidsskrift 09-2017.
10. Retningslinjer for kvinner med epilepsi. Konsensusrapport. 2017. Den norske legeforening (H Nordeng i forfattergruppen).
11. MS-svangerskap og ammeperiode. Nasjonal faglige retningslinjer 2017, <https://helsedirektoratet.no/retningslinjer/multipel-sklerose/seksjon?Tittel=familieplanlegging-graviditet-og-ammig-10796>(H Nordeng i forfattergruppen).

### Posters at national conferences:

17. **Sveberg L**, Nordeng H et al. Retningslinjer for kvinner med epilepsi, en oppdatering. Nevrodagene. 03.2017
18. **Gerd Marie E. Harris**, et al. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
19. **Gerd-Marie E. Harris**, Anne Gerd Granås, Ingunn Björnsdottir, Hedvig Nordeng Pharmacoeconomics & Drug Safety Research Group. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
20. **Bich Thuy Truong**, Hilde Ariansen, Hedvig Nordeng. SafeStart - a study promoting safe medication use in pregnancy in the era of real-world data. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
21. **Lene Maria Sundbakk**, et al. Behavioral effects at 5 years of age of prenatal exposure to benzodiazepines or z-hypnotics: A study from the Norwegian Mother and Child cohort study. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.

22. **Anna-Simone Frank**, Angela Lupattelli, KjetilRøysland, Hedvig Nordeng, Patterns and predictors of hypothyroid medication use in relation to pregnancy: a drug utilization study. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
23. **Lene Maria Sundbakk**, Hedvig Nordeng, Ragnhild Paulsen, Robert Lyle, Ragnhild Eskeland, Geir Kjetil Sandve and Sven Ove Samuelsen. PharmaTox Strategic Research Initiative. NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
24. **N. Ali, I. Björnsdóttir**. Intervjuer med veiledere: ledd i kartlegging av interessenters syn på praksisperioden, Farmasidagene, Oslo, 9-10 november. \*
25. **V. Gligorijevic, I. Björnsdóttir**. Fokusgrupper om farmasøytens holdninger og erfaringer med inhalasjonsveiledning, Farmasidagene, Oslo, 9-10 november.\*
26. **Bogosaljevic, D. Stevanovic, I. Björnsdóttir**. Farmakologisk tilgang til behandling av ADHD i Norge og Serbia V. Farmasidagene, Oslo, 9-10 november.\*
27. **H.T. Ngo, I. Björnsdóttir**. Medieomtale av ADHD-diagnose og -medisinering i Norge. Farmasidagene, Oslo, 9-10 november.\*
28. **B. Truong, H. Massfih, E. Thuy, H. Ariansen, H. Nordeng**. En intervensjonsstudie for å fremme sikker legemiddelbruk i svangerskapet, Farmasidagene, Oslo, 9-10 november.
29. **T. Nguyen, K. Svensberg, H. Nordeng**. Legemiddelkunnskap i befolkningen – fokus på reseptfrie smertestillende og antibiotika. - studieprotokoll, Farmasidagene, Oslo, 9-10 november.
30. E.R. Andersen, A. Baftiu, C. Christiansen, H. Selby Ebbestad, A. Gombos, H. Helm, I. Holth, Ø. Holte, **H. Nordeng**, A. Race, R.S.N. Saleh, M. Solberg, H. Willoch. Det Giftige Kors, Crux Venenifera, Farmasidagene, Oslo, 9 - 10 november.

*\* Ingunn Björnsdóttirs postere fra Farmasidagene i Norge og fra FIP ble gjenbrukt/hengt opp igjen på farmasiens dag på Island.*

#### **Oral presentational at national conferences:**

19. **Hedvig Nordeng**. Effect of pharmaceuticals on human neurotoxicity and neurodevelopment. NSFT, Farmakologisk vintermøte. 26.01.2017
20. **Hedvig Nordeng**. Building bridges over disciplinary boundaries - Experiences with the PharmaTox Strategic Research Initiative at the MN faculty. DURG Norway meeting. April 19<sup>th</sup> 2017
21. **Kristina Gervin** et al. "Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children diagnosed with ADHD". Oslo Epigenetics Minisymposium, Oslo, Norway. May 9<sup>th</sup> 2017.
22. **Kristina Gervin** et al. 'Long-term prenatal exposure to paracetamol is associated with DNA methylation differences in children diagnosed with ADHD' 47th Behavior Genetics Annual Meeting, Oslo, Norway. June 28<sup>th</sup> - July 1<sup>st</sup>
23. **Mollie Wood**. Misclassification of exposure. Norwegian Pharmacoepidemiology Association Annual Meeting. April 19<sup>th</sup> 2017.
24. **Ingunn Björnsdóttir**. Viktigheten av kvalitetsbevissthet: amfetamin og det islandske reseptregisteret. Norwegian Pharmacoepidemiology Association Annual Meeting. April 19<sup>th</sup> 2017.
25. **Anne Gerd Granås**. Student workshop: Writing up your PhD thesis – structure, level of detail, and enthusiasm! NFIF annual conference "Innovation in Pharmaceutical Sciences", 19-21 June 2017.
26. **Anne Gerd Granås**. Writing up your PhD thesis – structure, content and enthusiasm. Open Drug Academy Lecture at the University of Copenhagen. Part of the 3rd Nordic PhD meeting February 8-10<sup>th</sup> 2017 <http://dra.ku.dk/activities/2017/symposia-and-lectures/writing-your-phd-thesis---structure-content-and-enthusiams/>
27. **Hedvig Nordeng**. Is it safe to use paracetamol and antidepressants in pregnancy? And, how do we communicate risk to the public? NSFT, Poulsson seminar, Oslo, 12<sup>th</sup> December 2017.

#### Other national oral presentations:

28. **Hedvig Nordeng.** Emne kurs i psykofarmakologi, Legeforeningen, Oslo, 10.01.2017.
29. **Hedvig Nordeng.** Emnekurs OBSTET GYN kurs: Legemidler & graviditet, Legeforeningen, Oslo, 17.01.2017
30. **Hedvig Nordeng.** RELIS kurs OSLO, Riktig legemiddelbruk i klinisk praksis. Gravide, 13.02.2016
31. **Hedvig Nordeng.** RELIS kurs OSLO, Riktig legemiddelbruk i klinisk praksis. Ammende. 13.02.2016
32. **Hedvig Nordeng.** Building excellence and increasing quality in Norwegian research and education: The PharmaTox Honours Programme in Quantitative Life Sciences (QLS) INTPART NFR konferanse. March 2017
33. **Hedvig Nordeng.** Building excellence and increasing quality in Norwegian research and education: The PharmaTox Honours Programme in Quantitative Life Sciences (QLS). STUT møte, MatNat, September 2017.
34. **Hedvig Nordeng.** Amming og bruk av legemidler – alltid trygt? Ammeveiledningskurs trinn II Oslo, 17. oktober 2017
35. **Hedvig Nordeng.** Legemidler til gravide – hvilke råd tør og bør vi gi? Kjededager Boots, Gardemoen. Tirsdag 26. september 2017
36. **Hedvig Nordeng.** Farmakoterapi ved psykisk sykdom i svangerskapet og postpartum. Kurs i regi av Den norske legeforening Mental helse i svangerskapet. Rikshospitalet, Oktober 2017
37. **Hedvig Nordeng.** Alkohol, Legemidler i svangerskapet – nytt og nyttig. Kampanjeseminar Alkoholritt svangerskap, Oslo, 24. oktober 2017. Helsedirektoratet
38. **Hedvig Nordeng.** Effect of Prenatal Exposure to Medication on Human Neurodevelopment and Neurotoxicity. Research seminar Department of Pharmacology OUS/UiO. 30.11.2017
39. **Svensberg, Karin.** En pille for alt som er ille. Åpen dag på UiO for videregående studenter; 2017-03-09.
40. **Anne Gerd Granås.** GERSYK4403 – Farmakologi, Institutt for helse og samfunn UiO. Legemiddelsamstemming. 28.april.
41. **Anne Gerd Granås.** GERSYK4403 – Farmakologi, Institutt for helse og samfunn UiO. Legemiddelsamtaler. 28.april.
42. **Anne Gerd Granås** og Ingunn Tho. 3D printing og dronelevering av legemidler" - Hvordan påvirkes farmasøytens og pasientens fremtid av nye teknologiske løsninger? Høgskolen i Oslo og Akershus, Institutt for naturvitenskapelige helsefag, 4.april.
43. **Anne Gerd Granås** og Ingunn Tho. 3D-printing og drone levering av legemidler- Hva blir fremtidens farmasøytrolle i apotek? Nyttårsmøtet Norges Farmasøytisk Selskap, Oslo 10.januar.
44. **Anne Gerd Granås** og **Julie Wendelbo.** Tverrfaglig legemiddelgjennomgang i hjemmetjenesten i Oslo kommune. Nyttårsmøtet Norges Farmasøytiske Selskap, Oslo 10.januar.

#### Interviews and media coverage:

1. Italians, Brits drink more while pregnant: study, <https://www.msn.com/en-us/health/healthtrending/italians-brits-drink-more-while-pregnant-study/ar-BBzLGkb> AFP (04.12.2017)
2. Debate for Kvinnablaðið 24.4.2017: Ingunn Björnsdóttir. Misskilningureðmeðvituðhagraeðing [Misunderstanding or deliberate distortion]. <http://kvennabladid.is/2017/04/24/misskilningur-eda-medvituhagraeðing/>
3. Höskuldur Kári Schram. Villandi upplýsingar í lyfjagagnagrunni Landlæknis. Interview with Ingunn Björnsdóttir. Visir.is og TV stasjon Stöð 2, [www.visir.is/g/2017170509762](http://www.visir.is/g/2017170509762) (02.05.2017).
4. Skrev seg til leksikonjobb: [www.mn.uio.no/farmasi/english/research/groups/pharma-safe/news/2017/snl\\_nft\\_2017.jpg](http://www.mn.uio.no/farmasi/english/research/groups/pharma-safe/news/2017/snl_nft_2017.jpg)
5. Gravide i Norge drikker minst i Europa, [www.fhi.no/nyheter/2017/gravide-i-norge-drikker-minst-i-europa/](http://www.fhi.no/nyheter/2017/gravide-i-norge-drikker-minst-i-europa/)(31.03.2017)
6. Slik behandles depresjon i svangerskapet - Kan få konsekvenser for både mor og barn dersom behandling unngås: <http://www.klikk.no/foreldre/gravid/gravidhelse/antidepressiva-i-svangerskapet-1705976.ece> (30.01.17)
7. Bedre oppfølging med videoforelesninger. <http://www.farmatid.no/artikler/nyheter/bedre-oppfolging-med-videoforelesninger> (02.05.2017)



8. Barn kan få ADHD dersom mor tar mye paracetamol. <https://forskning.no/2017/09/noen-barn-kan-fa-adhd-hvis-mor-tar-mye-paracetamol> (23.09.2017)
9. Mye paracetamol i svangerskapet kan føre til ADHD. <https://www.nrk.no/vestfold/mye-paracetamol-i-svangerskapet-kan-fore-til-adhd-1.13706854> (26.09.2017)
10. Paracetamol (NRK Vestforlsendingen). <https://radio.nrk.no/serie/distriktsprogram-vestfold/DKVE21019217/26-09-2017>
11. Mors langvarig bruk av paracetamol knyttes til genpåvirkning og ADHD hos barnet. <https://titan.uio.no/node/2522> (19.10.2017)
12. Kvinner med migrene slutter med medisiner når de blir gravide. <https://forskning.no/helse-medisiner-smertelindring-hjernen-svangerskap/2017/08/kvinner-slutter-med-migrenemedisiner-nar>
13. SafeStart: Mange gravide har spørsmål og opplever svangerskapsrelaterte plager. [http://goruddalen.no/index.php?page=vis\\_nyhet&NyhetID=23701](http://goruddalen.no/index.php?page=vis_nyhet&NyhetID=23701) (14.12.2017)

#### Prizes

- H Nordeng. Titan prize for research dissemination, MatNat, UiO. <https://titan.uio.no/node/2651>

#### Grants

- A G Granås. Fulbright scholar, 2017/18. <https://fulbright.no/subhomemenu/current-fulbrighters/current-norwegian-fulbrighters/> <https://fulbright.no/wp-content/uploads/2016/06/17-18-norwegian-brochure-web.pdf>
- H Nordeng. Extrastiftelsen, one Phd position 2018-2020. SafeStart – safer use of medications in pregnancy.

#### National guest researchers:

**Anne-Katrine Eek**, Cand.pharm. RELIS Sør-Øst «Oral anticoagulants»

**Gro C Havnens**, Cand. Pharm. RELIS Sør-Øst «Treatment of Hyperemesis Gravidarum»

**Stine Kleppe Krogsrud**, Postdoctoral Research Fellow in the Department of Psychology at the University of Oslo.  
How do brain and cognition change during development? - A neuroscience perspective on brain development.  
March 21<sup>st</sup> 2017.